ReviewBreast cancer research : BCR2000
Transforming growth factor-beta and breast cancer: Tumor promoting effects of transforming growth factor-beta.
Review in Breast cancer research : BCR, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 157 citations in OpenAlex.
- Baseline T cell dysfunction by single cell network profiling in metastatic breast cancer patients.Journal for immunotherapy of cancer · 2019Trial
- Trial
- Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018Trial
- Trial
- NOS2 and COX2 impact the spatial landscape of CD8Redox biology · 2026Review
- Lutein reverses M2 macrophages polarization and exhibits antitumor effects on human triple-negative breast cancer cells.Molecular biology reports · 2026Article
- Signalling pathways in a nutshell: from pathogenesis to therapeutical implications in prostate cancer.Annals of medicine · 2025Review
- Association of exosomal miR17-92a cluster and target genes with breast cancer risk.Future oncology (London, England) · 2025Article
- Inflammatory signaling pathways in neutrophils: implications for breast cancer therapy.Annals of medicine and surgery (2012) · 2025Review
- Amelioration of breast cancer therapies through normalization of tumor vessels and microenvironment: paradigm shift to improve drug perfusion and nanocarrier permeation.Drug delivery and translational research · 2025Review
- TGFβ in malignant canine mammary tumors: relation with angiogenesis, immunologic markers and prognostic role.The veterinary quarterly · 2024Article
- Next-Cell Hypothesis: Mechanism of Obesity-Associated Carcinogenesis.Advances in experimental medicine and biology · 2024Review
- The immunomodulatory effects of Candida albicans isolated from the normal gastrointestinal microbiome of the elderly on colorectal cancer.Medical oncology (Northwood, London, England) · 2021Article
- Molecular Mechanisms of Antiproliferative and Apoptosis Activity by 1,5-Bis(4-Hydroxy-3-Methoxyphenyl)1,4-Pentadiene-3-one (MS13) on Human Non-Small Cell Lung Cancer Cells.International journal of molecular sciences · 2021Article
- Normal cells repel WWOX-negative or -dysfunctional cancer cells via WWOX cell surface epitope 286-299.Communications biology · 2021Article
- Cancer-Associated Adipocytes in Breast Cancer: Causes and Consequences.International journal of molecular sciences · 2021Review
- N-cadherin mediates the migration of bone marrow-derived mesenchymal stem cells toward breast tumor cells.Theranostics · 2021Article
- Effects of the Tumor Environment on Ion Channels: Implication for Breast Cancer Progression.Reviews of physiology, biochemistry and pharmacology · 2021Review
- In silico pathway analysis based on chromosomal instability in breast cancer patients.BMC medical genomics · 2020Article
- miR-106b-5p and miR-17-5p could predict recurrence and progression in breast ductal carcinoma in situ based on the transforming growth factor-beta pathway.Breast cancer research and treatment · 2019Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The transforming growth factor (TGF)-betas are potent growth inhibitors of normal epithelial cells. In established tumor cell systems, however, the preponderant experimental evidence suggests that TGF-betas can foster tumor-host interactions that indirectly support the viability and/or progression of cancer cells. The timing of this 'TGF-beta switch' during the progressive transformation of epithelial cells is not clear. More recent evidence also suggests that autocrine TGF-beta signaling is operative in some tumor cells, and can also contribute to tumor invasiveness and metastases independent of an effect on nontumor cells. The dissociation of antiproliferative and matrix associated effects of autocrine TGF-beta signaling at a transcriptional level provides for a mechanism(s) by which cancer cells can selectively use this signaling pathway for tumor progression. Data in support of the cellular and molecular mechanisms by which TGF-beta signaling can accelerate the natural history of tumors will be reviewed in this section.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.